icon Case report

Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD

Cannabidiol (CBD) rich products are successfully used in some countries for treating symptoms associated with autism spectrum disorder (ASD). Yet, CBD provides insufficient intervention in some individuals, or for some characterizing symptoms of ASD, raising the need for improved compositions. The current study presents a case wherein pure CBD was sufficient for treating ASD during childhood and early adolescence. However, it became insufficient during puberty accompanied by increased hyperactivity, agitation, and frequent severe aggressive behavior. Increasing the CBD dose did not result in significant improvement. Enriching the pure CBD with a carefully selected blend of anxiolytic and calming terpenes, resulted in gradual elimination of those aggressive events. Importantly, this was achieved with a significantly reduced CBD dose, being less than one-half the amount used when treating with pure CBD.

icon Article

Optimal Treatment with Cannabis Extracts Formulations Is Gained via Knowledge of Their Terpene Content and via Enrichment with Specifically Selected Monoterpenes and Monoterpenoids.

Differences between therapeutic effects of medical cannabis inflorescences and those of their extracts are generally attributed to the differences in administration form and in the resultant pharmacokinetics. We hypothesized that difference may further extend to the composition of the actually consumed drug. Cannabinoid and terpene contents were compared between commercial cannabis inflorescences (n = 19) and decarboxylated extracts (n = 12), and between inflorescences and decarboxylated extracts produced from them (n = 10). While cannabinoid content was preserved in the extracts, a significant loss of terpenes was evident, mainly in the more volatile monoterpenes

icon Article

Vapor Pressure, Vaping, and Corrections to Misconceptions Related to Medical Cannabis’ Active Pharmaceutical Ingredients’ Physical Properties and Compositions.

Medical cannabis products contain dozens of active pharmaceutical ingredients (APIs) derived from the cannabis plant. However, their actual compositions and relative doses significantly change according to the production methods. Product compositions are strongly dependent on processing step conditions and on components’ evaporation during those steps. Review of the documentation presented to caregivers and to patients show erroneous data or misinterpretation of data related to the evaporation, for example, cannabinoids’ boiling points, as well as confusions between terms, such as boiling, vaporization, and evaporation. Clarifying these aspects is
essential for caregivers, for researchers, and for developers of manufacturing processes. Original and literature data were analyzed, comparing composition changes during various processing steps and correlating

icon Press

Bazelet launches its Terpene enriched oil brand Femmican, dedicated to Women’s health.

icon Press

Bazelet launches its Bcann Oil brand, which is first-of-the kind, proprietary, terpene-enriched medical cannabis oils specially designed for medical needs such as women health, pain treatment, improved sleep and special needs of the elderly population
Bazelet, the largest medical company in Israel, has made a breakthrough in medical cannabis products, in launching multiple lines of terpene-enriched cannabis oils, each one of which being specifically designed for one of various indications, symptoms and personal needs. Bazelet terpene-enriched products are optimized for woman health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic), and for improved night sleep etc.

icon Article

Cannabis and Neurology

Bazelet’s scientific paper dealing with medical cannabis treatment in various neurological conditions was published in the Neurology journal, the official journal of the Israel Neurological association.

icon article

White Paper on Maximizing Therapeutic Outcomes: Synergistic Effects of Terpenes and THC in Medical Cannabis

This White Paper delves into the current understanding of terpene-THC interactions and their implications for optimizing medical cannabis treatment. By evaluating recent research, including a notable study by the Bazelet Medical Cannabis Group, we explore how specific terpenes can synergize with THC to enhance CB1 receptor activity, potentially augmenting the therapeutic efficacy of cannabis-based treatments. We will further explore the potential for terpene-THC combinations to reduce the required THC dosage, thereby minimizing adverse effects and improving patient outcomes.

נגישות